Adagrasib 200 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 200 mg

Reference Brands: Krazati (USA)

Category: Oncology Cancer Care

Adagrasib is a small-molecule inhibitor that selectively binds to the mutant KRAS G12C protein, preventing cancer cell growth and survival. It is primarily used in certain non-small cell lung cancers (NSCLC) and colorectal cancers with the KRAS G12C mutation.

Product Description:

Adagrasib inhibits KRAS G12C, a mutant form of a protein that was considered undruggable for four decades. KRAS switches cell growth signalling on and off; the G12C mutation leaves it stuck on. Adagrasib binds irreversibly to the cysteine that the mutation introduces, locking the protein in its inactive state — so it attacks only mutant KRAS and leaves the normal protein alone.

It is used for non-small cell lung cancer carrying the KRAS G12C mutation after prior systemic therapy, and in combination with cetuximab for KRAS G12C colorectal cancer. About thirteen percent of lung adenocarcinomas carry this mutation, so molecular testing selects patients; without it the drug has no role. Its long half-life and central nervous system penetration are points of difference from sotorasib. Diarrhoea, nausea, fatigue and raised liver enzymes are common, and QT prolongation requires ECG monitoring. It is a CYP3A4 substrate and inhibitor, so co-medication needs review.

Sourcing notes. Originator product, on patent, no generic. KRAS G12C testing must be available in the destination market or the product cannot be prescribed. Supply is through authorised distribution, and oncology formulary decisions rather than price determine uptake.